Montelukast Definition
Montelukast is a selective leukotriene receptor antagonist. It is used as the sodium salt, but doses are expressed in terms of the base; Montelukast sodium 10.37 mg is equivalent to about 10 mg of Montelukast. The mean bioavailability of Montelukast is 64% and it is more than 99% bound to plasma proteins.
The Montelukast is a leukotrine receptor antagonist (LTRA) used for the maintenance treatment of asthma, chronic asthma attacks and to relive symptoms of seasonal allergies.18
It is usually administered orally. Montelukast is a CysLT1antagonist; it blocks the action of leukotriene D4 (and secondary ligands LTC4 and LTE4) on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction
otherwise caused by the leukotriene and results in less inflammation. Montelukast is an orally active, highly selective LTRA that inhibits the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity.
The Montelukast is a leukotrine receptor antagonist (LTRA) used for the maintenance treatment of asthma, chronic asthma attacks and to relive symptoms of seasonal allergies.18
It is usually administered orally. Montelukast is a CysLT1antagonist; it blocks the action of leukotriene D4 (and secondary ligands LTC4 and LTE4) on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction
otherwise caused by the leukotriene and results in less inflammation. Montelukast is an orally active, highly selective LTRA that inhibits the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity.